This Drug Discovery TOE depicts trends across biopharmaceuticals for psoriasis, hepatocellular carcinoma, Crohn's disease, migraine, HIV, and hepatitis B infection, among others. Clinical trial analysis of Etanercept biosimilar is also presented.
The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.
The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
1. Advancements in Drug Discovery and Development
FDA-approved Drug to Provide Affordable Psoriasis Treatment Option
Ramucirumab Proves Promising Against Hepatocellular Carcinoma and Bladder Cancer
Monoclonal Antibody Targeting Specific Cell Marker in Crohn’s Disease
Calcitonin Gene-Related Peptide (CGRP) as a Drug Target for Migraine Prevention
Breakthrough Therapy for Multi-drug Resistant HIV Infection
Enhancing Biologics Manufacturing Capabilities
Accelerating Biosimilar Commercialization
Groundbreaking Treatment for X-linked Hypophosphatemia
Novel Immunotherapies for Hepatitis B and HIV
2. Drug Development Analysis and Key Contacts
Clinical Trial Analysis of Etanercept Biosimilar